ABSTRACT OBJECTIVES This study investigated whether patients with patent foramen ovale (PFO) have an increased risk of stroke due to permanent pacemaker (PPM)/implantable cardioverter-defibrillator (ICD) implantation.
B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N
I S S N 1 9 3 6 -8 7 9 8 / $ 3 6 . 0 0 and/or the presence of an associated atrial septal aneurysm have been associated with an increased risk of stroke in patients with PFO (16) . Similarly, DeSimone et al. (17) reported their experience with 3 patients who presented with lead thrombus, PFO, and stroke, presumably due to paradoxical embolism.
Although the risk of cryptogenic stroke in patients with lead thrombosis and PFO is physiologically plausible, to our knowledge, there has been no systematic evaluation to study the effect of device implantation on stroke outcomes in a population consisting of only PFO patients. We compared the incidence of ischemic stroke in PFO patients with or without device implantation from our large institutional database.
METHODS
In this retrospective study, we identified patients were excluded from the study, unless they experienced a stroke/TIA before the closure procedure.
We used electronic medical records to collect demographic information, baseline clinical characteristics, medical history, medications, and laboratory test results.
Patients were followed until the end of 2012 or until the primary endpoint, whichever occurred earlier. Considering device implantation as the dependent variable, a propensity score was generated for each patient through a regression model using variables listed in Table 1 Before propensity score matching, patients in the device group were older and were more often male ( 52.47%, p < 0.001). There were also significant differences in medication use, with patients in the device group receiving more medications compared with patients in the no device group ( Table 1) . After propensity score matching, the 2 groups (n ¼ 231 patients each) were identical with equivalent baseline characteristics and medications.
Ischemic stroke occurred in 6 patients in each group ( Table 2 ). The primary outcome was not different between the 2 groups (2.6% vs. 2.6%, p ¼ 1.0). The event rate for stroke was 3.03 events/ 1,000 patient-years in the no device group and 2.82 events/1,000 patient-years in the device group. The time-to-event analysis showed that there was no Poddar et al.
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difference in stroke outcome between the 2 groups (p ¼ 0.748; odds ratio: 0.342; 95% confidence interval: 0.003 to 3.833). In patients who had a stroke (12 patients), the annual event rate was 0.33 events/ year in the no device group, whereas it was 0.20 events/year for patients in the device group.
Further analysis in the matched cohort showed that of 22 events (stroke and TIA), 19 occurred in patients with atrial fibrillation. Subgroup analysis in patients with atrial fibrillation revealed that 10 patients in the device group experienced a neurological event compared with 9 patients in the no device group (7.4% vs. 7.0%, p ¼ 1.00). In patients who did not have atrial fibrillation, no ischemic stroke event occurred after device implantation, whereas the event rate in the no device group was found to be 2.22
events/1,000 patient-years.
DISCUSSION
In our study, we found that implantation of an electrical cardiac device with an electrode in the Values are mean AE SD or n (%).
5,711 non-PFO patients). They concluded that patients
ACE ¼ angiotensin-converting enzyme; COPD ¼ chronic obstructive pulmonary disease.
Poddar et al. 2.0%, p < 0.0001). Our study differs from theirs in few important ways. First, our patient population consists of PFO patients only, as we want to specifically study whether device implantation has any impact on stroke outcome in patients with the defect. Second, they included patients with previous stroke/TIA, whereas we did not because previous stroke itself is an important predictor of future stroke (23) .
We also considered many other baseline variables, including medications in our study. We believe that STUDY LIMITATIONS. The limitations associated with any retrospective study apply to this analysis, including selection bias and differences in unadjusted baseline characteristics. Correction for these factors using propensity score matching was performed, but is not equivalent to a true randomization.
It is important to note that, before propensity matching, patients in the device group were receiving more aggressive antithrombotic therapy and other medications (warfarin, aspirin, statin). This difference is a limitation when comparing the risk of thromboembolic complications. Worse clinical characteristics (e.g., atrial fibrillation, age, heart failure, low ejection fraction) and medication use are likely to be associated with patients who require a device implantation. However, propensity score matching Using device implantation as the dependent variable, a propensity score was generated for each patient through a regression model using variables listed in Table 1 . Each patient in the device group was matched to a patient in the no device group based on the closest propensity score. The method yielded 1:1 matched groups from the total population.
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Stroke in Patent Foramen Ovale and Device Another limitation of our study is the low event rate. Our strict exclusion criteria may well have accounted for low number of events in our study group. We limited our study to the majority of patients who may not be considered high risk and thus presents a dilemma for interventionalists concerning the decision to close the PFO. In the presence of these limitations, further studies from larger centers, collaborative studies, or possibly a randomized trial may produce more definite answers.
CONCLUSIONS
In patients with PFO and no previous episode of an ischemic neurological event, implantation of a PPM or ICD is not associated with an increased risk of an ischemic stroke event in the subsequent 4 years.
Evaluation for other stroke risk factors, including atrial fibrillation, is imperative to reduce the risk of neurological events.
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